Table 1.
Patient baseline demographics
| Parameter | No. (%) (n=262) |
|---|---|
| Age, mean±SD (yr) | 57.3±11.6 |
| Sex (male/female) | 204 (77.9)/58 (22.1) |
| BMI, mean±SD (kg/m2) | 23.4±3.2 |
| Underlying disease | |
| Diabetes | 46 (17.6) |
| Hypertension | 97 (37) |
| Ischemic heart disease | 2 (0.8) |
| Cerebrovascular disease | 4 (1.5) |
| Karnofsky performance score | |
| ≥ 80% | 254 (96.9) |
| 50%-70% | 8 (3.1) |
| MSKCC risk group | |
| Favorable | 23 (11.2) |
| Intermediate | 131 (63.6) |
| Poor | 52 (25.2) |
| Unknown | 56 |
| Heng risk group | |
| Favorable | 41 (17) |
| Intermediate | 160 (66.4) |
| Poor | 40 (16.6) |
| Unknown | 22 |
| Treatment duration, median (range, mo) | 4.3 (0.1-68.4) |
| Metastatic site | |
| Lung | 204 (77.3) |
| Liver | 44 (16.7) |
| LN | 116 (43.9) |
| Bone | 89 (33.7) |
| Brain | 23 (8.7) |
| Other | 36 (13.6) |
| Clinical T stage | |
| T1 | 25 (9.5) |
| T2 | 32 (12.2) |
| T3 | 71 (27.1) |
| T4 | 21 (8) |
| Tx | 115 (43.6) |
| Clinical N stage | |
| N1 | 37 (14.1) |
| Nx | 109 (42) |
| Renal embolization | 16 (6.1) |
| Nephrectomy | 124 (47.3) |
| Pathologic T stage | |
| T1 | 22 (8.3) |
| T2 | 27 (10.3) |
| T3 | 53 (20.1) |
| T4 | 8 (3) |
| Tx | 152 (57.9) |
| Pathologic N stage | |
| N1 | 12 (4.6) |
| Nx | 154 (59.1) |
| Fuhrmann grade | |
| 1 | 7 (2.7) |
| 2 | 42 (16) |
| 3 | 82 (31.3) |
| 4 | 35 (13.4) |
| Unknown | 96 (36.6) |
| Histology | |
| Clear cell, pure | 178 (67.4) |
| Mixed | 34 (12.9) |
| Papillary | 5 (1.9) |
| Chromophobe | 2 (0.8) |
| Unclassified | 5 (1.9) |
| Unknown | 38 (15.1) |
| Primary treatment drug | |
| Target therapy | 127 (48.5) |
| Sunitinib | 92 (35.1) |
| Sorafenib | 17 (6.5) |
| Pazopanib | 18 (6.9) |
| Immunotherapy | 135 (51.5) |
| Secondary treatment drug | 96 |
| Target therapy | 83 (86.5) |
| Sunitinib | 33 (39.8) |
| Sorafenib | 23 (27.7) |
| Pazopanib | 3 (3.6) |
| Everolimus | 21 (25.3) |
| Axitinib | 3 (3.6) |
| Immunotherapy | 13 (13.5) |
| Second-line best response (RECIST criteria 1.0) | 69 (100) |
| PD | 28 (40.6) |
| SD | 22 (31.9) |
| PR | 16 (23.2) |
| CR | 3 (4.3) |
| F/U loss or death | 27 |
| Second-line progression free survival, median (range, mo) | 6.5 (4.9-8.0) |
| Target therapy/Immunotherapy, median (range, mo) | 7.1 (5.8-8.4)/2.1 (1.8-2.4) |
| Second-line overall survival, median (range, mo) | 15.3 (8.9-21.7) |
| Target therapy/Immunotherapy, median (range, mo) | 16.6 (10-22.5)/8.6 (0.1-27.5) |
SD, standard deviation; BMI, body mass index; MSKCC, Memorial Sloane Kettering Cancer Center; LN, lymph node; RECIST, Response Evaluation Criteria in Solid Tumors; PD, progressive disease; SD, stable disease; PR, partial response; CR, complete response; F/U, follow-up.